HROW Stock Forecast & Price Target

Harrow Inc. is well-positioned to capitalize on the growing market for biosimilars, which is projected to exceed 40% market share in various therapeutic categories, thereby aligning with healthcare cost reduction goals. The company's VEVYE product has demonstrated significant traction, with a 22% quarter-over-quarter revenue growth reaching $22.6 million in 3Q25 and capturing a 10.5% share of the national dry eye disease market. Additionally, projections suggest a revenue run rate exceeding $250 million in 4Q27, approximately four times higher than the actuals reported in 2Q25, indicating strong potential for long-term revenue and margin expansion.

Harrow Inc faces significant challenges that contribute to a negative outlook for its stock, primarily due to the potential failure of its pipeline products to achieve favorable clinical data or regulatory approval, which could adversely impact the company's valuation. The company encounters several risks, including lower-than-expected market adoption rates, difficulties in securing new product acquisitions, and the burden of outstanding debt, all of which could materially affect its financial performance. Furthermore, as a small company with limited resources, Harrow might need to reduce its sales and marketing initiatives and raise capital to sustain operations, raising concerns about potential shareholder dilution.